Program Description
As chronic lymphocytic leukemia (CLL) moves to targeted, chemotherapy-free care, community oncology pharmacists in medically integrated practices are now central to therapy selection, safe initiation, and long-term management. This program provides practical guidance on using fixed-duration venetoclax regimens, covalent and non-covalent BTK inhibitors, and CAR T-cell referral pathways while managing real-world challenges such as tumor lysis syndrome, cardiovascular risk, and drug interactions. The session also addresses the 2026 Medicare Part D and IRA changes, including maximum fair prices and the Medicare Transaction Facilitator, to help oncology pharmacies maintain access, manage reimbursement, and avoid negative margins in CLL care.Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 13, 2026
Expiration date: May 13, 2027
Learner level: Foundational, Intermediate
Time to complete activity: .75 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Adapt clinical evidence, guidelines, and patient-specific considerations into frontline regimen selection for patients with chronic lymphocytic leukemia (CLL)
- Examine evidence-based strategies to optimize safety protocols, manage therapy-related toxicities, and enhance adherence support for patients receiving novel targeted therapies in relapsed/refractory CLL
- Customize Medicare Transaction Facilitator enrollment, data matching, and refund reconciliation workflows to avoid negative margins for dispensing entities when acquisition costs exceed the maximum fair prices
Karen M. Fancher, PharmD, BCOP
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, PA
Clinical Pharmacy Specialists – Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, PA
Evan Slater, PharmD
Director, Pharmacy Services
Rocky Mountain Cancer Centers
Denver, CO
Accreditation
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-26-108-H01-P. The activity is available for CE credit through May 13, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Karen Fancher, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP, Daphne Davis, PharmD, BCOP; Emily Tyler; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.
Evan Slater, PharmD has the following relevant financial relationships with ineligible companies to disclose: Consultant: Bristol Myers Squibb, Janssen, Merck; Speakers Bureau: BeOne, Bristol Myers Squibb, Janssen
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational
purposes and do not constitute any form of professional advice or referral.
Discussions concerning drugs, dosages, and procedures may reflect the clinical
experience of the author(s) or be derived from the professional literature or
other sources and may suggest uses that are investigational in nature and not
approved by the labeling or indications. Participants are encouraged to refer
to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here